반응식
Cl.[NH:2]1[CH2:7][CH2:6][C:5](=[CH:8][C:9]2[CH:10]=[C:11]([CH:23]=[CH:24][CH:25]=2)[O:12][C:13]2[CH:18]=[CH:17][C:16]([C:19]([F:22])([F:21])[F:20])=[CH:15][N:14]=2)[CH2:4][CH2:3]1.[N:26]1[CH:31]=[CH:30][N:29]=[CH:28][C:27]=1[NH:32][C:33](=O)[O:34]C1C=CC=CC=1.NC1C=NC=CN=1>>[N:26]1[CH:31]=[CH:30][N:29]=[CH:28][C:27]=1[NH:32][C:33]([N:2]1[CH2:7][CH2:6][C:5](=[CH:8][C:9]2[CH:25]=[CH:24][CH:23]=[C:11]([O:12][C:13]3[CH:18]=[CH:17][C:16]([C:19]([F:22])([F:20])[F:21])=[CH:15][N:14]=3)[CH:10]=2)[CH2:4][CH2:3]1)=[O:34]참가 물질
4
실험 절차
Following the procedure in Example 1, Step 6, 2-(3-piperidin-4-ylidenemethyl-phenoxy)-5-trifluoromethyl-pyridine hydrochloride (150 mg, 0.40 mmol, from Example 1, Step 5) and phenyl pyrazin-2-ylcarbamate (261 mg, 1.2 mmol, prepared according to the procedure described in Synthesis, 1997, 1189-1194 from aminopyrazine) were used to provide the title compound (24 mg). MS (APCI 10V) AP+ 456.2, 376.2, 335.2, AP− 454.2, 435.1; 1H NMR (400 MHz, CD3OD) δ ppm 2.43-2.50 (m, 2H) 2.56-2.62 (m, 2H) 3.54-3.61 (m, 2H) 3.64-3.70 (m, 2H) 6.46 (s, 1H) 6.98-7.05 (m, 2H) 7.10-7.17 (m, 2H) 7.40 (td, J=7.72, 0.67 Hz, 1H) 8.06-8.11 (m, 1H) 8.16 (d, J=2.68 Hz, 1H) 8.28 (dd, J=2.68, 1.54 Hz, 1H) 8.43 (ddd, J=2.56, 1.71, 0.85 Hz, 1H) 9.04 (d, J=1.56 Hz, 1H).
후처리
- customprepared
출처 및 근거
- ORD 기록
- ord-f26809a8a59c495aa199e1de8e974960
- 출처 데이터셋
- uspto-grants-2011_10
- 특허 번호
- US08044052B2
연결된 노트
불러오는 중…